Description
Gefitinib, marketed under the brand name GEFTINAT, It is an prescription medication that has been approved gefitinib in May 2003, for non-small cell lung cancer (NSCLC). It was approved as monotherapy for the treatment of people with locally advanced or metastatic NSCLC after failure of both platinum-based and docetaxel chemotherapies.
What is GEFTINAT (Gefitinib) ?
Geftinat 250mg Tablet is used in the treatment of non-small cell lung cancer. It is used in patients in which it has spread to other parts of the body, who have abnormal epidermal growth factor receptor (EGFR) genes, and who have not had previous treatment for cancer.
Gefitinib is the first selective inhibitor of epidermal growth factor receptor’s (EGFR) tyrosine kinase domain. Thus gefitinib is an EGFR inhibitor. The target protein (EGFR) is a member of a family of receptors (ErbB) which includes Her1(EGFR), Her2(erb-B2), Her3(erb-B3) and Her4 (Erb-B4).
How to order approved “GEFTINAT (Gefitinib) for tablets” Medicine?
GEFTINAT (Gefitinib) tablets is a prescription medicine, it can be accessed through the Named Patient Program (NPP) for treatment in the following city of India – Bengaluru, Delhi, Chennai, Hyderabad, Mumbai, Pune, Kolkata, Ahmedabad, Gurgaon. To inquire about the cost price of purchasing GEFTINAT and arranging delivery to your location, please get in touch with Mr. Rakesh at +91 9910645395 or send an enquiry to info@cancermedicinesnetwork. We assure you of the quality of the product and guarantee delivery in accordance with your specific requirements.
We can ship to :
Verve Biosciences offers assistance in importing the anti-cancer medication GEFTINAT (Gefitinib) for tablets. To inquire about the total cost of GEFTINAT (Gefitinib) for tablets in various countries, including UAE, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela, as well as Europe (such as UK, Hungary, Ireland, Latvia, Slovakia, Czech Republic, Belgium, Lithania, Greece, Spain, Maldova, Germany, Sweden, Italy, Bulgaria, Romania, Montenegro, Russia), and other countries like Zimbabwe, Australia, and New Zealand, Canada, Philippines, USA, South Africa, Thailand, China, Pakistan, Kazakhstan, Uzbekistan, Zambia, Kuwait, Sri Lanka, Singapore, Hong Kong, Afghanistan, Turkey, Malaysia, Qatar, Japan, Nepal, and many other countries. please reach out to us. We will provide you with the necessary information regarding the pricing and availability of GEFTINAT (Gefitinib) for tablets in the desired locations.
How to Get Access
If the Brand Name medication “GEFTINAT (Gefitinib) for tablets” is not approved or unavailable in your country, patients, physicians, and distributors/suppliers have the option to purchase and import it from Verve Biosciences. To begin the process, you can make an enquiry, and we will assist you in calculating the total cost to buy “GEFTINAT (Gefitinib) for tablets” online and arrange delivery to your location. To proceed, we will require a prescription from your treating doctor, and in certain countries, an import license may also be necessary. Throughout the process, our Patient Support team will provide guidance and support.
Verve Biosciences Pvt. Ltd.
Contact Person : Mr Rakesh Khanna
Email: info@cancermedicinesnetwork.com
Mobile: 91 9910645395
WhatsApp: +919910645395
FAQ's
How much does GEFTINAT cost?
The GEFTINAT price in India usually can vary depending on the wholesaler/pharmacy you visit. GEFTINAT is available as a brand name drug only, a generic version is not yet available.
What is the best price for Gefitinib?
Please contact at urgent@cancermedicinesnetwork.com : (+91) 9910645395 for Gefitinib price India. We take the guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Can I get GEFTINAT (Gefitinib) for tablets even if I am not based in India?
The Verve Biosciences helps patients in accessing or importing GEFTINAT (Gefitinib), not approved in their home country against the legitimate prescription and in conformity with the all local laws and regulations of their home country.
